Trial Profile
Effectiveness and feasibility of afatinibe in EGFR mutated non-small cell lung cancer patients with postoperative recurrence. -Phase II study-
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2020
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Dec 2014 New trial record